SCHEMBL26506565

SCHEMBL26506565

COC(=O)c1ccccc1Oc1nc(Nc2cccc(C(F)(F)F)c2)ncc1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 4/20 0.55
▸ PRKAA2 P54646 1/20 0.55
▸ PRKAA1 Q13131 1/20 0.55
▸ ULK2 Q8IYT8 1/20 0.55
▸ HDAC3 O15379 1/20 0.49
▸ HDAC1 Q13547 1/20 0.49
▸ HDAC2 Q92769 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ MAPK8 P45983 1/20 0.47
▸ EGFR P00533 3/20 0.46
▸ CTSC P53634 1/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ RXFP1 Q9HBX9 2/20 0.45
▸ BRAF P15056 1/20 0.45
▸ LCK P06239 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506588 0.89 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506585 0.89 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2EGFR
SCHEMBL26506556 0.86 ULK1 (0.61) ULK1PRKAA2PRKAA1ULK2EGFR
SCHEMBL26506566 0.85 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506554 0.84 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506543 0.83 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2EGFR
SCHEMBL26506548 0.82 ULK1 (0.67) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506592 0.82 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506547 0.82 ULK1 (0.63) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506589 0.81 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback